Bowen D - Search Results

1

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, Symeonidis A, Cermâk J, Hellström-Lindberg E, Stauder R, Sanz G, Mittelman M, Holm MS, Malcovati L, Mądry K, Germing U, Tatic A, Savic A, Almeida AM, Gredelj-Simec N, Guerci-Bresler A, Beyne-Rauzy O, Culligan D, Kotsianidis I, Itzykson R, van Marrewijk C, Blijlevens N, Bowen D, de Witte T; EUMDS Registry Participants. de Swart L, et al. Among authors: bowen d. Haematologica. 2020 Mar;105(3):632-639. doi: 10.3324/haematol.2018.212217. Epub 2019 Jun 6. Haematologica. 2020. PMID: 31171638 Free PMC article.

2

Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression.

Culligan DJ, Bowen DT, May A, White D, Padua RA, Burnett AK. Culligan DJ, et al. Among authors: bowen dt. Br J Haematol. 1995 Mar;89(3):675-7. doi: 10.1111/j.1365-2141.1995.tb08389.x. Br J Haematol. 1995. PMID: 7734379

3

Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters.

Bowen DT, Culligan D, Beguin Y, Kendall R, Willis N. Bowen DT, et al. Leukemia. 1994 Jan;8(1):151-5. Leukemia. 1994. PMID: 8289479

4

Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.

Aul C, Bowen DT, Yoshida Y. Aul C, et al. Among authors: bowen dt. Haematologica. 1998 Jan;83(1):71-86. Haematologica. 1998. PMID: 9542325 Review.

5

Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?

Bowen DT, Hellstrom-Lindberg E. Bowen DT, et al. Leuk Res. 2001 Jan;25(1):19-21. doi: 10.1016/s0145-2126(00)00100-4. Leuk Res. 2001. PMID: 11137556 No abstract available.

6

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.

Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J; UK MDS Guidelines Group. Bowen D, et al. Br J Haematol. 2003 Jan;120(2):187-200. doi: 10.1046/j.1365-2141.2003.03907.x. Br J Haematol. 2003. PMID: 12542475 Free article. No abstract available.

7

No increase in age-specific incidence of myelodysplastic syndromes.

Germing U, Strupp C, Kündgen A, Bowen D, Aul C, Haas R, Gattermann N. Germing U, et al. Among authors: bowen d. Haematologica. 2004 Aug;89(8):905-10. Haematologica. 2004. PMID: 15339672

8

Latency of onset of de novo myelodysplastic syndromes.

Wu PS, Hay AE, Thomas GE, Bowen DT. Wu PS, et al. Haematologica. 2004 Nov;89(11):1392-4. Haematologica. 2004. PMID: 15531463

9

Thalidomide therapy for low-risk Myelodysplasia.

Bowen D, MacIlwaine L, Cavanagh J, Killick S, Culligan D, Thomson E, Mufti G. Bowen D, et al. Leuk Res. 2005 Feb;29(2):235-6. doi: 10.1016/j.leukres.2004.05.017. Leuk Res. 2005. PMID: 15607375 No abstract available.

10

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.

Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P. Vey N, et al. Among authors: bowen d. J Clin Oncol. 2006 Jun 1;24(16):2465-71. doi: 10.1200/JCO.2005.03.9503. Epub 2006 May 1. J Clin Oncol. 2006. PMID: 16651646 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,511 results

Search Page

Filters